tbuckley/cabot-search huggingface dataset:
RARE-21GLIOBLASTOMA WITH LEPTOMENINGEAL AND INTRAMEDULLARY METASTASES AT TIME OF INITIAL DIAGNOSIS IN AN ELDERLY PATIENT: A CASE REPORT
Authors: Wendy Sherman
Journal: Neuro-Oncology (2015)

Unfortunately, glioblastoma multiforme (GBM) continues to be an incurable, highly aggressive central nervous system malignancy. Extracranial dissemination of GBM is exceedingly rare, with most case reports indicating dissemination either as a post-surgical result or at time of disease progression. Here we present a case of an 85 year old woman who initially presented with confusion, falls, and episodic aphasia. MRI of the brain demonstrated a 2.2cm enhancing mass in the left occipital lobe. Patient was subsequently found to have leptomeningeal and intramedullary metastases at the time of initial diagnosis. Biopsy of the occipital mass was consistent with MGMT methylated GBM. Given patient's age and performance status, along with recent data supporting the efficacy of temozolomide monotherapy in elderly patient with MGMT methylated glioblastoma, patient elected to withhold brain radiation, proceeding with temozolomide monotherapy with palliative radiation therapy to her spinal deposits. She unfortunately experienced a rapid decline, with an overall survival of 6 weeks. This case presents a patient where MGMT monotherapy did not stabilize her disseminated disease. Further, the lack of radiographic evidence of direct tumor extension into the cerebrospinal fluid suggests a more invasive tumor phenotype allowing for the early dissemination. Further tumor biology research is required in this subset of patients regarding the mechanism for extracranial disease dissemination.
Thyroid Dysfunction in Patients with Diffuse Large B-Cell Lymphoma Receiving Lenalidomide May be Mediated By TNF-α
Authors: Wade T Iams, Megan L Hames, Judy Peih-Ying P Tsai, Kimberly B Dahlman, Mahsa Talbott, Kristy L. Richards, Nishitha M. Reddy
Journal: Blood (2014)
Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population.
Authors: Robert B. Jenkins, Eric J Bergstralh, Elai Davicioni, R. Jeffrey Karnes, Karla V. Ballman, Stephanie Fink, Peter C. Black, Mercedeh Ghadessi, Timothy J. Triche, George G Klee, Thomas M. Kollmeyer, Ismael A Vergara, Anamaria Crisan, Nicholas Erho, Thomas Sierocinski, Christine Buerki, Rachel Carlson, Diane E Grill, Benedikt Zimmermann, Zaid Haddad
Journal: Journal of Clinical Oncology (2012)

175 Background: The efficient delivery of adjuvant and salvage therapy after radical prostatectomy in patients with prostate cancer is hampered by a lack of biomarkers to assess the risk of clinically significant recurrence and progression. Methods: Mayo Clinic Radical Prostatectomy Registry (RP) patient specimens were selected from a case-control cohort with 14 years median follow-up for training and initial validation of an expression biomarker genomic classifier (GC). An independent, blinded case-cohort study of high-risk RP subjects was used to validate GC, comparing the performance of GC to a multivariate logistic regression clinical model (CM) and GC combined with clinical variables (genomic-clinical classifier, GCC) for predicting clinical recurrence (defined as positive bone or CT scan within 5 years after biochemical recurrence). The concordance index (c-index) and Cox model were used to evaluate discrimination and estimate the risk of clinical recurrence. Results: In the training subset (n=359), both GC and GCC had a c-index of 0.90 whereas CM had a c-index of 0.76. In the internal validation set (n=186), GC and GCC had a c-index of 0.76 and 0.75, while CM had a c-index of 0.69. In an independent high-risk study (n=219), GC and GCC had a c-index of 0.77 and 0.76, while CM had a c-index of 0.68. In subset analysis of Gleason score 7 patients within the high-risk group, GC and GCC showed improved discrimination with c-index of 0.78 and 0.76, respectively compared to 0.70 for CM. In the high-risk group, the risk of recurrence by GC model score quartiles at 5 years after RP was estimated at 1%, 5%, 5% and 18%. Conclusions: The GC model shows improved performance over CM in the prediction of clinical recurrence in a high-risk cohort and in subset analysis of Gleason score 7 patients. The addition of clinical variables to the GC model did not significantly contribute to classifier performance in patients with high-risk features. We are further testing the performance of the GC and GCC models and their usefulness in guiding decision-making (e.g., for the adjuvant therapy setting) in additional studies of prostate cancer clinical risk groups.
Rituximab in the Treatment of Secondary Autoimmune Neutropenia.
Authors: Aleksandra A. Pivkova, Lidija L. Cevreska, Zlate Z. Stojanoski, Irina I. Panovska, Nikola N. Siljanoski, Sonja S. Genadieva Stavrik, Svetlana S. Krstevska Balkanov, Sanja S. Trajkova, Borce B. Georgievski
Journal: Blood (2005)
Thiazide Diuretics Protect Bones as Well as Hearts
Authors: Anita Slomski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CD99 is a therapeutic target on disease stem cells in myeloid malignancies
Authors: Stephen S. Chung, William S. Eng, Wenhuo Hu, Mona Khalaj, Francine E. Garrett-Bakelman, Montreh Tavakkoli, Ross L. Levine, Martin Carroll, Virginia M. Klimek, Ari M. Melnick, Christopher Y. Park
Journal: Science Translational Medicine (2017)

Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are initiated and sustained by self-renewing malignant stem cells; thus, eradication of AML and MDS stem cells is required for cure. We identified CD99 as a cell surface protein frequently overexpressed on AML and MDS stem cells. Expression of CD99 allows for prospective separation of leukemic stem cells (LSCs) from functionally normal hematopoietic stem cells in AML, and high CD99 expression on AML blasts enriches for functional LSCs as demonstrated by limiting dilution xenotransplant studies. Monoclonal antibodies (mAbs) targeting CD99 induce the death of AML and MDS cells in a SARC family kinase-dependent manner in the absence of immune effector cells or complement, and anti-CD99 mAbs exhibit antileukemic activity in AML xenografts. These data establish CD99 as a marker of AML and MDS stem cells, as well as a promising therapeutic target in these disorders.
CHARACTERISTICS, IN-HOSPITAL AND LONG-TERM CLINICAL OUTCOMES OF NONAGENARIAN AMI PATIENTS COMPARED WITH OCTOGENARIAN AMI PATIENTS
Authors: Ki Hong Lee, Young Keun Ahn, Myung Ho Jeong, Donghan Kim, Shung Chull Chae, Young Jo Kim, Jei Keon Chae, Myeong Chan Cho, Chong Jin Kim
Journal: Journal of the American College of Cardiology (2012)
Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia
Authors: Giovanni Del Poeta, Maria Ilaria Del Principe, Pietro Bulian, Cristina Simotti, Francesco Buccisano, Fabrizio Luciano, Antonella Zucchetto, Licia Ottaviani, Luca Maurillo, Chiara Sarlo, Annalisa Biagi, Laura Giannì, Alessio Pio Perrotti, Adriano Venditti, Paolo de Fabritiis, Valter Gattei, Sergio Amadori
Journal: Blood (2010)
Trump signs order targeting key elements of Affordable Care Act
Authors: Michael McCarthy
Journal: BMJ (2017)

In the first hours of his presidency, US president Donald Trump issued an executive order that directed federal agencies in his new administration to take immediate action to slow, impede, or halt the implementation any provision of the Affordable Care Act that imposed a “burden” on individuals, healthcare providers, insurers, and states.

“It is the policy of my administration to seek the prompt repeal of the Patient Protection and Affordable Care Act,” Trump wrote. “In the meantime, pending such repeal, it is imperative for the executive branch to ensure that the law is being efficiently implemented, take all actions consistent with law to minimize …
Chimerism Analysis of Free Circulating DNA in the Prediction of Relapse in Patients with Acute Leukemia Treated with Stem Cell Transplantation,
Authors: Mahmoud Aljurf, Hala Abalkhail, Amal Alseraihy, Mouhab Ayas, Abdullah Al-Jefri, Ali Al-Ahmari, Asim F Belgaumi, Claudia Ulrike Walter, Naeem A. Chaudhri, Fahed Almhareb, Hassan El-Solh, Maher Albitar
Journal: Blood (2011)
SNP-Based Mapping Arrays Reveal High Genomic Complexity in Monoclonal Gammopathies: From the MGUS to Myeloma Status
Authors: Lucía López-Corral, Maria Eugenia Sarasquete, Sílvia Beà, Ramón García-Sanz, Maria Victoria Mateos, Marcos González, Luis Antonio Corchete, Joan Bladé, Albert Oriol-Rocafiguera, Miguel Hernandez, Pilar Giraldo, Jose Hernández, Jesús M Hernández-Rivas, Jesús F San Miguel, Norma C. Gutierrez
Journal: Blood (2011)
An online tool to assess the quality of research programs.
Authors: Renee Yvonne Smith, Patricia A. Hurley, Michael A Thompson, Dax Kurbegov, Nicholas J. Robert
Journal: Journal of Clinical Oncology (2016)

e18153 Background: Many community-based research programs do not have resources to support a quality assurance program and rely exclusively on external audits. Although valuable, external audits are retrospective and may not result in preventive actions. The ASCO Research Program Quality Assessment Tool was developed to help community-based research sites develop a quality program and exceed the minimum standards of conducting clinical research. The original tool was released in 2014 and featured a manual and resources, including a self-assessment checklist tool. In 2015, an online version of the checklist tool was developed for sites to assess their research program in a way that would be sustainable and not burdensome. The tool covers four key domains: general research program administration; program management; protocol management; and data collection, management, and quality control. Methods: A pilot study was conducted with community-based research programs to assess the utility and feasibility of the tool. Participants completed a series of questions about their research program’s experience and infrastructure. They conducted the quality assessment and completed a feedback survey on the process. Results: 18 research programs participated in the pilot study. Participants were from a variety of types of research programs. All respondents indicated that the tool was: user-friendly, comprehensive, and instructions and data entry were easily understood. They felt the summary report was useful and accurately reflected the quality of their program. Respondents reported that the tool identified specific areas to improve their program (72.2%) and they planned to make changes based on what was learned (72.2%). Respondents indicated that they would use the tool for their program (83.3%) and thought the manual was helpful (88.9%). Conclusions: The new online version of the ASCO Research Program Quality Assessment Tool helps research programs create and maintain an internal quality assurance program in a way that is sustainable, user-friendly, and not burdensome. The tool will enable sites to collect data and assess performance longitudinally. The online tool is available online via www.asco.org/communityresearchforum.
Myc-associated zinc finger protein mediates the tumor specific expression of PPAR gamma 1 in human breast cancer cells
Authors: Xin Wang, R. Chase Southard, Melinda E. Wilson, Michael W. Kilgore
Journal: Cancer Research (2005)

4514  Peroxisome Proliferator-activated Receptor (PPAR) is a nuclear hormone receptor that binds specific response elements (PPRE) in the promoter of target genes. Three PPAR isoforms (α,β/δ,γ), each coded by a different gene, have been reported. We have previously shown that PPAR γ1 is highly over expressed in human breast cancer cells, and the high expression of PPAR γ1 in human breast cancer cells is driven by a tumor specific promoter. These data indicate that the pA1 promoter is the major promoter used in human breast cancer cell lines for PPAR γ1 transcription. We cloned a 3kb promoter region that is upstream of exon A1 of PPAR γ1 and identified a highly GC-rich (90%) 263bp minimum promoter fragment of pA1 by using standard deletion analysis. To obviate the difficulty of working with such a GC-rich promoter and to speed the identification of the transcription factor(s) mediating tumor specific expression of PPARγ1,we have merged microarry analysis with the Transcription Element Search Software, TESS analysis. These analysis identified 29 potential transcription factors that could bind to one of 209 different binding site within the 263bp fragment. These data were used in conjunction with microarry data comparing the expression of thousand of gene between MCF-7 and Normal Human Mammary Epitheial Cell (HMEC). We identified the only one of the transcription factor, MAZ (Myc-associated zinc finger protein, Genebank Accession: BC041629), that was highly over expressed in MCF-7 compared to HMEC. Gel shift assay demonstrated that MAZ is able to bind to the putative MAZ response element in the tumor specific promoter but not in the PPAR γ1 promoter used in HMEC. Using both MAZ over expression and silencing RNA approaches, these data indicates that MAZ plays a critical role in the tumor specific transcriptional activation of PPAR γ1 by binding to the tumor specific promoter region and possibly promoting PPAR γ1 promoter switching in tumor cells. Our gene chip data also showed GADD45 (the Growth Arrest and DNA Damage-inducible gene 45) mRNA level is regulated by PPAR γ1. When MAZ is transiently expressed in HMEC, GADD45 mRNA level also changes dramatically. As GADD45 is already known as an important regulator of cell cycle progression, apoptosis and DNA repair, and this points to one possible mechanism of PPARγ1 action in breast cancer. Together these data begin to define the mechanism of the tumor-specific expression of PPARγ1 provides unique insights into novel targets for therapeutic intervention.
Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.
Authors: Steven D. Gore, Anchalee Jiemjit, Lewis B. Silverman, Timothy Aucott, Stephen Baylin, Hetty Carraway, Tianna Dauses, Tamer Fandy, James Herman, Judith E. Karp, Jonathan D. Licht, Anthony J. Murgo, Rosalie Odchimar-Reissig, B. Douglas Smith, James A. Zwiebel, Elizabeth Sugar
Journal: Blood (2006)
Graft-Versus-Host Disease (GVHD) Induced Graft-Versus-Leukemia (GVL) Effect: More Impact on Later Relapse and Disease-Free Survival Following Reduced Intensity Conditioning
Authors: Daniel J. Weisdorf, Mei-Jie Zhang, Mukta Arora, J. Douglas Rizzo, Mary M. Horowitz, Mary Eapen
Journal: Blood (2011)
High Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: Comparison of Four Preparative Regimens.
Authors: Emilio P. Alessandrino, Letizia Zenone Bragotti, Anna A. Colombo, Alessandra Algarotti, Paolo Bernasconi, Margherita Maffioli, Daniela Caldera, Alessandro Corso, Elisa Rumi, Daniela Troletti, Mario Lazzarino
Journal: Blood (2005)
A Prospective Study of Cardiotoxicity In Non-Hodgkin Lymphoma Patients with RAPID-Infusion Rituximab
Authors: Mariano Provencio, Antonio Sanchez, Miriam Mendez, Constanza Maximiano, Blanca Cantos, Juan A Vargas, Pablo Tutor, Susana Mellor, Miguel A. Canales, Pilar España
Journal: Blood (2008)
Quantitative PCR Assessment of JAK2 Mutational Status in Philadelphia-Chromosome Negative Chronic Myeloproliferative Disorders - The JAK2 V617F Mutation Is an Event in an Early Stem Cell and the Clonal Involvement of Different Haematopoietic Cells Varies between Individual Patients.
Authors: Thomas S. Larsen, Hans C. Hasselbalch, Niels Pallisgaard
Journal: Blood (2006)
Early FDG-PET Scan Confirms Its Prognostic Impact Also in Localized Stage, ABVD Treated Hodgkin Lymphoma Patients.
Authors: Luigi Rigacci, Benedetta Puccini, Francesco Merli, Caterina Stelitano, Patrizia Pregno, Chiara Fraulini, Flavia Salvi, Rita Emili, Ida Capodanno, Umberto Vitolo, Teodoro Chisesi, Alessandro Levis, Anna Marina Liberati, Alberto Bosi
Journal: Blood (2008)
Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies
Authors: Giovanni Roti, Annie Carlton, Kenneth N. Ross, Michele Markstein, Kostandin Pajcini, Norbert Perrimon, Andrew L. Kung, Warren S. Pear, Stephen C. Blacklow, Jon C Aster, Kimberly Stegmaier
Journal: Blood (2011)
Nanosafety: Validating Metal‐Organic Framework Nanoparticles for Their Nanosafety in Diverse Biomedical Applications (Adv. Healthcare Mater. 2/2017)
Authors: Stefan Wuttke, Andreas Zimpel, Thomas Bein, Simone Braig, Katharina Stoiber, Angelika Vollmar, Dominik Müller, Kirsten Haastert‐Talini, Jörn Schaeske, Meike Stiesch, Gesa Zahn, Alexander Mohmeyer, Peter Behrens, Oliver Eickelberg, Deniz A. Bölükbas, Silke Meiners
Journal: Advanced Healthcare Materials (2017)

Metal-organic frameworks (MOFs) are a promising platform for the synthesis of porous nanoparticles for diverse medical applications. Stefan Wuttke, Silke Meiners, and co-workers comprehensively investigate the nanosafety and hence the general applicability of different MOF nanoparticles for distinct fields of medical applications (e.g. drug delivery or implant coatings) in article 1600818. Data presented here suggest the need to evaluate the nanosafety of each MOF nanomaterial with respect to their particular medical application.
Novel psychoactive substances: identifying and managing acute and chronic harmful use
Authors: Derek K Tracy, David M Wood, David Baumeister
Journal: BMJ (2017)

#### What you need to know

Identifying and managing acute drug related harms and problematic substance misuse cuts across medical specialties. Data suggest that clinicians are seeking readily accessible information on novel psychoactive substances (NPS), incorrectly known as “legal highs.” Clinicians may encounter acutely disturbed or unwell patients, individuals with harm or dependency related to chronic NPS use, and those reporting incidental consumption that might require psychoeducation and monitoring. Such assessments will have more successful and meaningful outcomes if clinicians are aware of the spectrum of NPS available and how they might affect their patient.

The linked clinical update1 describes the different classes of NPS and their effects. This article provides practical advice to the non-specialist on how to approach an assessment of individuals using NPS, including examples of acute and chronic use.

A sensitive, non-judgmental approach is essential. Key aspects of the history are applicable in all scenarios. Boxes 1 and 2 cover specific issues relevant to emergency and longer term presentations. Patients may be concerned about being criticised for using drugs, and they might be uncertain of, but worried about, the potential harms and available services for those using NPS. Individuals can also be fearful of legal consequences of disclosure, and the principle and limits of confidentiality should be discussed. Adopt an empathic line of questioning, such as “I can imagine it might be difficult or worrying to talk about drug/NPS use. My role is to try understand …
AAV3 Capsid Is Superior for In Vivo Gene Transfer to Human Hepatocytes Compared to Serotypes 5 and 8 in a Mouse/Human Chimeric Model
Authors: Roland W. Herzog, Brad E. Hoffman, Irene Zolotukhin, Katherine A. High, Arun Srivastava, Ype P. de Jong, Koen Vercauteren, Jing Xiao
Journal: Blood (2015)
Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation.
Authors: Lihua E. Budde, Katherine A Guthrie, Brian G. Till, Thomas Chauncey, Oliver W. Press, John M. Pagel, Stephen Petersdorf, William Bensinger, Leona Holmberg, Andrei R. Shustov, David G Maloney, Ajay K. Gopal
Journal: Blood (2009)
Intra-arterial migration of a fractured endoscopic needle
Authors: Edward Lake, Joanne Puleston, Finn Farquharson
Journal: Endoscopy (2017)

A 53-year-old man with chronic pancreatitis presented with abdominal pain and sepsis. Imaging revealed a liver abscess secondary to distal biliary obstruction. Following drainage of his abscess, the patient underwent endoscopic retrograde cholangiopancreatography (ERCP) with placement of a fully covered metal biliary stent across a 2-cm suspicious shouldered and irregular low common bile duct stricture. A pancreatic head malignancy was suspected at ERCP and on computed tomography (CT) imaging. The regional specialist hepatobiliary multidisciplinary team (MDT) recommended endoscopic ultrasound with fine needle aspiration (EUS-FNA).
Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation
Authors: Giuseppe Patti, Markus Lucerna, Ilaria Cavallari, Elisabetta Ricottini, Giulia Renda, Ladislav Pecen, Fabio Romeo, Jean-Yves Le Heuzey, Josè Luis Zamorano, Paulus Kirchhof, Raffaele De Caterina
Journal: Journal of the American College of Cardiology (2017)
Gene Expression Profiling of Plasma Cell Dyscrasias: The Role of IGH Translocations in the Heterogeneity of Multiple Myeloma.
Authors: Antonino Neri, Michela Mattioli, Luca Agnelli, Sonia Fabris, Luca Baldini, Fortunato Morabito, Silvio Bicciato, Donata Verdelli, Daniela Intini, Lucia Nobili, Lilla Cro, Giancarlo Pruneri, Vincenzo Callea, Caterina Stelitano, Luigia Lombardi
Journal: Blood (2004)
B-Diffuse Large Cell Lymphoma and Nonrandon Karyotipic Abnormalities in Ph Negative Cells of Patients with Ph-Positive Chronic Myeloid Leukemia Imatinib Treated.
Authors: E. Luño, C. Sanzo, M. González, A. Alonso, F. Jonte, M. Balbin, F. Fresno, A. Ramírez
Journal: Blood (2007)
Novel Direct Evidence That Adult Bone Marrow-Derived Very Small Embryonic Like (VSEL) Stem Cells Are Mobilized into Peripheral Blood - Leukopheresis as a Potential Tool To Isolate Pluripotent Stem Cells for Therapeutic Pruposes.
Authors: Magda Kucia, Marcin Wysoczynski, Wu Wan, Mariusz Z. Ratajczak
Journal: Blood (2007)
3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets
Authors: Jianjiong Gao, Matthew T. Chang, Hannah C. Johnsen, Sizhi Paul Gao, Brooke E. Sylvester, Selcuk Onur Sumer, Hongxin Zhang, David B. Solit, Barry S. Taylor, Nikolaus Schultz, Chris Sander
Journal: Genome Medicine (2017)

Many mutations in cancer are of unknown functional significance. Standard methods use statistically significant recurrence of mutations in tumor samples as an indicator of functional impact. We extend such analyses into the long tail of rare mutations by considering recurrence of mutations in clusters of spatially close residues in protein structures. Analyzing 10,000 tumor exomes, we identify more than 3000 rarely mutated residues in proteins as potentially functional and experimentally validate several in RAC1 and MAP2K1. These potential driver mutations (web resources: 3dhotspots.org and cBioPortal.org) can extend the scope of genomically informed clinical trials and of personalized choice of therapy.